Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non–small cell lung cancer
JA Engelman, PA Jänne - Clinical Cancer Research, 2008 - AACR
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors gefitinib and erlotinib are
effective therapies for non–small cell lung cancer patients whose tumors harbor somatic …
effective therapies for non–small cell lung cancer patients whose tumors harbor somatic …
Resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non–small cell lung cancer
PS Hammerman, PA Jänne, BE Johnson - Clinical cancer research, 2009 - AACR
Gefitinib and erlotinib are ATP competitive inhibitors of the epidermal growth factor receptor
(EGFR) tyrosine kinase and are approved around the world for the treatment of patients with …
(EGFR) tyrosine kinase and are approved around the world for the treatment of patients with …
Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non–small-cell lung cancers dependent on the epidermal growth factor receptor …
KSH Nguyen, S Kobayashi, DB Costa - Clinical lung cancer, 2009 - Elsevier
Abstract Most advanced Non–Small-cell lung cancers (NSCLCs) with activating epidermal
growth factor receptor (EGFR) mutations (exon 19 deletions or L858R) initially respond to …
growth factor receptor (EGFR) mutations (exon 19 deletions or L858R) initially respond to …
Mechanisms of resistance to EGFR TKIs and development of a new generation of drugs in non‐small‐cell lung cancer
T Kosaka, E Yamaki, A Mogi… - BioMed Research …, 2011 - Wiley Online Library
Gefitinib and erlotinib, which are epidermal growth factor receptor‐(EGFR‐) specific tyrosine
kinase inhibitors (TKIs), are widely used as molecularly targeted drugs for non‐small‐cell …
kinase inhibitors (TKIs), are widely used as molecularly targeted drugs for non‐small‐cell …
[HTML][HTML] Mechanisms of acquired resistance to first-and second-generation EGFR tyrosine kinase inhibitors
Patients with non-small-cell lung cancer (NSCLC) whose tumours harbour activating
mutations within the epidermal growth factor receptor (EGFR) frequently derive significant …
mutations within the epidermal growth factor receptor (EGFR) frequently derive significant …
Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non–small-cell lung cancer
Ten percent of North American patients with non–small-cell lung cancer have tumors with
somatic mutations in the gene for the epidermal growth factor receptor (EGFR) …
somatic mutations in the gene for the epidermal growth factor receptor (EGFR) …
Acquired resistance of lung adenocarcinoma to EGFR-tyrosine kinase inhibitors gefitinib and erlotinib
Y Xu, H Liu, J Chen, Q Zhou - Cancer biology & therapy, 2010 - Taylor & Francis
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib
and erlotinib, are the first targeted therapy drugs approved for the treatment of advanced non …
and erlotinib, are the first targeted therapy drugs approved for the treatment of advanced non …
Strategies for overcoming resistance to EGFR family tyrosine kinase inhibitors
G Giaccone, Y Wang - Cancer treatment reviews, 2011 - Elsevier
The first-generation epidermal growth factor receptor tyrosine kinase inhibitors erlotinib and
gefitinib have been incorporated into treatment paradigms for patients with advanced non …
gefitinib have been incorporated into treatment paradigms for patients with advanced non …
Uncommon epidermal growth factor receptor mutations in non-small cell lung cancer and their mechanisms of EGFR tyrosine kinase inhibitors sensitivity and …
E Massarelli, FM Johnson, HS Erickson, II Wistuba… - Lung Cancer, 2013 - Elsevier
Therapy targeted against the epidermal growth factor receptor (EGFR) has demonstrated
dramatic tumor responses and favorable clinical outcomes in a select group of non-small …
dramatic tumor responses and favorable clinical outcomes in a select group of non-small …
New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer
The management of non–small cell lung carcinoma (NSCLC) has been transformed by the
observation that lung adenocarcinomas harboring mutations in epidermal growth factor …
observation that lung adenocarcinomas harboring mutations in epidermal growth factor …
相关搜索
- lung cancer acquired resistance
- kinase inhibitors acquired resistance
- kinase inhibitors egfr tyrosine
- lung cancer kinase inhibitors
- egfr tkis mechanisms of resistance
- egfr tyrosine acquired resistance
- lung cancer egfr tkis
- egfr tyrosine lung adenocarcinoma
- lung cancer mechanisms of resistance
- kinase inhibitors lung adenocarcinoma
- lung adenocarcinoma acquired resistance